Research programme: glycogen synthase kinase-3 inhibitors - Kemia
Latest Information Update: 26 Feb 2008
At a glance
- Originator Kemia
- Mechanism of Action Glycogen synthase kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes mellitus; Mood disorders
Most Recent Events
- 22 Jun 2005 Preclinical trials in Affective disorders in USA (PO)
- 22 Jun 2005 Preclinical trials in Diabetes mellitus in USA (PO)